We’re making an even greater impact against viral diseases and breaking new ground in cancer and inflammation to help build a healthier world for all.
Explore Our Pipeline- Our Therapeutic Leadership
- Pursuing What’s Next
Our Therapeutic Leadership
For more than 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed and we introduced options to help make prevention efforts more effective, and we’ve helped cure millions of people with hepatitis C around the world. Our decades of research in emerging viruses allowed us to deliver the first approved treatment for COVID-19. And together with Kite, a Gilead Company, which is focused on cell therapy, we’re making an impact in multiple types of cancer.
Known for our commitment to innovation and access, we are poised to meet our 2019 ambition to deliver 10+ transformative therapies by 2030.
Pursuing What’s Next
We’re relentlessly committed to our pursuit of a healthier world for all people.
We’re building on our legacy in virology by helping to end the HIV epidemic for everyone, everywhere, including through the development of long-acting options for PrEP (pre-exposure prophylaxis), by aiming to eliminate hepatitis C as a public health problem, and pursuing new options for infectious diseases with unmet need and preparing for future outbreaks or pandemics. In oncology, we’re driving innovative discovery to positively impact the lives of more than 500,000 people with cancer around the world by 2030. In inflammation, we’re committed to addressing unmet patient needs with the development of next-generation therapies for inflammatory and fibrotic diseases such as primary biliary cholangitis, inflammatory bowel disease, and lupus.
It will take more than medicine alone to solve the greatest challenges in virology, oncology and inflammation. Beyond our science, we’re committed to working with communities and partners around the world to improve access to care and support systems that advance health and opportunity.
Therapeutic Areas
Virology
We’re building on a legacy of transformation in virology.
Oncology
We’re disrupting the status quo in how cancer treatments are developed to accelerate new therapies.
Inflammation
We’re unlocking next-generation therapies across inflammatory and fibrotic diseases.
OUR IMPACT
New medicines delivered by 2030, as part of our ambitions set in 2019
Clinical programs across oncology, virology and inflammation
Invested in research and development in 2024
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We have developed more than 25 life-changing medicines to treat, prevent and transform conditions that impact millions of people and are rapidly growing our portfolio through research, development and external collaborations.